Aroma Sticks
…ctive. It would be recommended that the hospice reintroduce the Aroma Sticks to the service.…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 7,621–7,680 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
angiotensin II1angiotensin II inhibitors1angiotensin II receptor blocker1angiotensin converting enzyme (ACE) inhibitor1angiotensin converting enzyme inhibitors-angiotensin II receptor blockers1anifrolumabAbstract1anlotinib-induced1antacid1anthelmintic medication1anthelmintics1anti PD-11anti-4-1BB1anti-B7-H3 antibody‒drug conjugate1anti-BAFF1anti-CD38 mAb1anti-CD38 monoclonal antibodies1anti-CD401anti-CD40 agonist antibody1anti-CD47 monoclonal antibody1anti-CGRP monoclonal antibodies1anti-CTLA-4 antibody1anti-CTLA-4 mAb1anti-CTLA4 antibody1anti-HER2 antibody-drug conjugates1anti-Ly6G1anti-MDA5 antibody1anti-Mullerian Hormone1anti-Müllerian hormone1anti-OA pharmacological agents1anti-OX401anti-PD-(L)1-based1anti-PD-1 ICB1anti-PD-L1 avelumab1anti-Parkinson’s drugs1anti-Sjögren’s syndrome antigen A1anti-TIM-31anti-Th/To-positive1anti-VEGF agents1anti-VEGFR21anti-anginal medication1anti-cancer compounds1anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors1anti-diabetic agents1anti-fibrotic medications1anti-histamines1anti-hypertensive drugs1anti-infectious agents1anti-inflammatory drugs1anti-inflammatory reliever1anti-interferon1anti-oestrogen medications1anti-pan γδ x CD1231anti-pan γδ x CD123 bispecific antibody1anti-programmed cell death protein 11anti-programmed cell death protein 1 (PD1)1anti-programmed cell death protein-1/programmed death-ligand 11anti-programmed death (ligand) 11anti-programmed death-ligand 1 (PD-(L)1)1anti-programmed death-ligand 1 (PD-L1)1anti-programmed death-ligand 1 antibodies1
Articles mentioning drugs
10,506 articles · page 143 of 876intravenous magnesium sulphateintravenous aminophyllinesubcutaneous adrenalineintravenous ketamineintravenous short-acting beta agonist (SABA)SABAsevere asthmaasthma
…03 to 2.21). There were no frequent serious adverse events. The intravenous magnesium sulphate group had a lower hospitalisation rate (RR=1.52, 95% CI 1.26 to…
PRO-C4Idiopathic pulmonary fibrosis (IPF)IPF
…sely correlated with the change in lung function. High baseline PRO-C4 was associated with increased mortality risk in PFBIO (HR 2.55 …
colchicinecoronary disease
…ho received low-dose colchicine compared with placebo. Low-dose colchicine was associated with a higher volume of calcified plaque, partic…
Ciprofolpropofolcolorectal cancerFirst Affiliated Hospital of Xi’an Jiaotong University
…its gastrointestinal motility, potentially contributing to POI. Ciprofol, a newer general anaesthetic characterised by the addition of a…
ezetimiberosuvastatinhigh-intensity statinmoderate-intensity statinacute myocardial infarctionAMINCT04499859Institutional Review Board of Seoul St. Mary’s HospitalHigh-intensity statin therapy
…randomised 1:1 to receive either moderate-intensity statin with ezetimibe (rosuvastatin 5 mg with ezetimibe 10 mg) or high-intensity stat…
ABS001imiquimodCervical cancer
…y was conducted using low-, mid-, and high-dose formulations of ABS001 to explore potential bell-shaped immunologic effects.Results In…
1022 Engineering a tri-specific antibody targeting PD-1, IL-2, and butyrate to reprogram cold tumors
butyrateCold solid tumorsmicrosatellite stable colorectal cancersPD-1 checkpoint blockadeimmunotherapy
…latory agents interleukin-2 (IL-2) and the microbial metabolite butyrate are under investigation for tumor microenvironment modulation. …
pembrolizumabnivolumabatezolizumabcemiplimabavelumabdurvalumabdocetaxelsolid tumorsClinicalTrials.govN Engl J Med+1 more
…arms (n=8,684 patients) with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult soli…
lisocabtagene maraleucelmosunetuzumabglofitamabaxicabtagene ciloleucelBsAbsB-cell lymphomasFLfollicular lymphomaLBCLrelapsed/refractory B-cell lymphomas+2 more
…32%). In FL, CAR-T products such as axicabtagene ciloleucel and lisocabtagene maraleucel achieve CR rates up to 94%, with median durations of remission …
MaaT034-treatedMaaT034melanomaMC38 tumors
…he capability of MaaT034 microbes to produce these metabolites. MaaT034-treated mice displayed a reduction of the size of cecum, which translat…
Compound Amultiple myelomacutaneous lymphoma
…8 with immunoproteasomes. Treatment of patient tumor cells with Compound A significantly increased the cytotoxic effect of allogeneic and …